

Identifying Appropriate High-Risk Patients and Managing Drug-Drug Interactions With Outpatient Antiviral Therapy: Assessing Current Best Practices in 2023

Resource	Address
Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: A retrospective cohort study [published online ahead of print, 2023 Feb 10]. <i>Lancet Infect Dis.</i> 2023;S1473-3099(23)00011-7.	https://pubmed.ncbi.nlm.nih.gov/36780912/
Ahmad FB, Cisewski JA, Anderson RN. Provisional mortality data — United States, 2021. <i>MMWR Morb Mortal Wkly Rep.</i> 2022;71:597-600.	https://www.cdc.gov/mmwr/volumes/71/wr/mm7117e1.htm
Centers for Disease Control and Prevention. COVID Data Tracker Weekly Review. Updated April 14, 2023.	https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
Centers for Disease Control and Prevention. HIV and COVID-19 Basics. Last reviewed: July 12, 2022.	https://www.cdc.gov/hiv/basics/covid-19.html
Centers for Disease Control and Prevention. People with Certain Medical Conditions.	https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
Centers for Disease Control and Prevention. Symptoms of COVID-19. Updated October 26, 2022.	https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
Centers for Disease Control and Prevention. Therapeutic Management of Nonhospitalized Adults with COVID-19. Updated April 20, 2023.	https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/
Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. <i>BMJ.</i> 2020;371:m3862.	https://pubmed.ncbi.nlm.nih.gov/33097561/
Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: A population-based cohort study. <i>Ann Intern Med.</i> 2023;176:77-84.	https://pubmed.ncbi.nlm.nih.gov/36508742/
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. <i>N Engl J Med.</i> 2020;383:1757-1766.	https://pubmed.ncbi.nlm.nih.gov/32329974/
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. <i>N Engl J Med.</i> 2022;386:305-315.	https://pubmed.ncbi.nlm.nih.gov/34937145/
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. <i>N Engl J Med.</i> 2022;386:1397-1408.	https://pubmed.ncbi.nlm.nih.gov/35172054/
Infectious Diseases Society of America (IDSA). Management of drug interactions with nirmatrelvir/ritonavir (Paxlovid™): Resource for clinicians. Last updated May 6, 2022.	https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-paxlovid-drug-interactions-resource-5-6-22-v1.1.pdf
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. <i>N Engl J Med.</i> 2022;386:509-520.	https://pubmed.ncbi.nlm.nih.gov/34914868/

Lagevrio™ (molnupiravir). Fact sheet for healthcare providers: Emergency use authorization for Lagevrio™ (molnupiravir) capsules. Merck Sharp & Dohme LLC; 2023.	https://www.fda.gov/media/155054/download
Li HL, Cheung BM. The proportion of adult Americans at risk of severe COVID-19 illness. <i>J Gen Intern Med.</i> 2021;36:259-261.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586862/
Liverpool Drug Interactions Group. Assessing a patient for Paxlovid (nirmatrelvir/ritonavir). Updated March 16, 2023.	https://www.covid19-druginteractions.org/prescribing_resources/paxlovid-patient-assessment
Mazzitelli M, Mengato D, Sasset L, et al. Molnupiravir and nirmatrelvir/ritonavir: Tolerability, safety, and adherence in a retrospective cohort study. <i>Viruses.</i> 2023;15:384.	https://pubmed.ncbi.nlm.nih.gov/36851598/
Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. <i>Clin Infect Dis.</i> 2023;76:e342-e349.	https://pubmed.ncbi.nlm.nih.gov/35653428/
National Institutes of Health. COVID-19 Treatment Guidelines. Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. Updated March 6, 2023.	https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/
Pandit JA, Radin JM, Chiang D, et al. The COVID-19 rebound study: A prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls [published online ahead of print, 2023 Feb 22]. <i>Clin Infect Dis.</i> 2023;ciad102.	https://pubmed.ncbi.nlm.nih.gov/36810665/
Paxlovid (nirmatrelvir tablets; ritonavir tablets). Fact sheet for healthcare providers: Emergency use authorization for Paxlovid™. Pfizer Inc; 2023.	https://labeling.pfizer.com/ShowLabeling.aspx?id=16474&format=pdf
Rommasi F, Nasiri MJ, Mirsaiedi M. Antiviral drugs proposed for COVID-19: Action mechanism and pharmacological data. <i>Eur Rev Med Pharmacol Sci.</i> 2021;25:4163-4173.	https://pubmed.ncbi.nlm.nih.gov/34156698/
Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. <i>Ann Intern Med.</i> 2020;173:773-781.	https://pubmed.ncbi.nlm.nih.gov/32783686/
US Department of Health and Human Services. COVID-19 Outpatient Therapeutics. Clinical Decision Aid for Ages 12+ years. December 2022.	https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/COVID-Therapeutics-Decision-Aid.pdf
Veklury® (remdesivir). Prescribing information. Gilead Sciences, Inc; 2023.	https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. Preprint. <i>medRxiv.</i> 2022;2022.06.21.22276724.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258292/